CLINICAL TRIALS PROFILE FOR MAXALT

All Clinical Trials for Maxalt

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00360282 ↗	Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines?	Completed	Merck Sharp & Dohme Corp.	N/A	2006-08-01	The purpose of this study is to determine if Rizatriptan, a migraine medication, lowers motion sickness in migraine sufferers.
NCT00360282 ↗	Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines?	Completed	University of Pittsburgh	N/A	2006-08-01	The purpose of this study is to determine if Rizatriptan, a migraine medication, lowers motion sickness in migraine sufferers.
NCT00397254 ↗	Two Rizatriptan Prescribing Portions for Treatment of Migraine	Completed	Merck Sharp & Dohme Corp.	Phase 4	2006-12-01	The primary objective of this study is to evaluate a clinical limit (CL) of rizatriptan (9 rizatriptan 10mg Orally Disintegrating Tablet (ODT) per month) versus (vs.) a formulary limit (FL) of rizatriptan (27 rizatriptan 10mg ODT per month) as measured by the number of days of migraine per month.
NCT00397254 ↗	Two Rizatriptan Prescribing Portions for Treatment of Migraine	Completed	Clinvest	Phase 4	2006-12-01	The primary objective of this study is to evaluate a clinical limit (CL) of rizatriptan (9 rizatriptan 10mg Orally Disintegrating Tablet (ODT) per month) versus (vs.) a formulary limit (FL) of rizatriptan (27 rizatriptan 10mg ODT per month) as measured by the number of days of migraine per month.
NCT00471952 ↗	Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache	Completed	Merck Sharp & Dohme Corp.	Phase 3	2007-04-01	The purpose of this study is to evaluate the effect of rizatriptan, alone or combined with caffeine for treating acute attacks of migraine. Each subject will have 3 months to treat 3 acute migraine headache attacks. Each subject will be dispensed one box containing 3 packets of study medication labeled for Headache #1, Headache #2, or Headache #3. Each packet wil contain either Maxalt 10mg MLT or a Maxalt placebo (sugar pill), and a capsule containing either caffeine 75mg or a capsule containing placebo (sugar). One headache will be treated with a combination of Maxalt 10mg MLT and caffeine. Another headache will be treated with a combination of Maxalt 10mg MLT and a capsule containing placebo. A third headache will be treated with just placebo. Neither the subject, the study coordinator, or your study doctor will know in which order you will receive the three different treatments. This information is available in case of emergency.

Clinical Trial Conditions for Maxalt

Condition Name

Condition Name for Maxalt
Intervention	Trials
Migraine	3
Migraine With Aura	1
Migraine Without Aura	1
Migraine, Acute	1

Condition MeSH

Condition MeSH for Maxalt
Intervention	Trials
Migraine Disorders	8
Headache	3
Migraine with Aura	1
Motion Sickness	1

Clinical Trial Locations for Maxalt

Trials by Country

Trials by Country for Maxalt
Location	Trials
United States	15

Trials by US State

Trials by US State for Maxalt
Location	Trials
California	2
Pennsylvania	2
New York	1
Minnesota	1
Washington	1

Clinical Trial Progress for Maxalt

Clinical Trial Phase

Clinical Trial Phase for Maxalt
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	4
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for Maxalt
Clinical Trial Phase	Trials
Completed	8
Withdrawn	1

Clinical Trial Sponsors for Maxalt

Sponsor Name

Sponsor Name for Maxalt
Sponsor	Trials
Merck Sharp & Dohme Corp.	7
Henry M. Jackson Foundation for the Advancement of Military Medicine	1
Robert W. Baloh	1

Sponsor Type

Sponsor Type for Maxalt
Sponsor	Trials
Industry	7
Other	6